← ANALYST RATINGS · TIPRANKS
GeneDx Holdings (WGS): analyst forecast and price target
Analyst consensus
Strong Buy5 Buy0 Hold0 Sell
Ratings of 5 analysts in the last 3 months · top analysts only12-month forecast
Based on 5 price targets given in the last 3 months, the average target is $85.80, the highest $103, the lowest $63.00. The average is +34.9% from the last price of $63.61.
| Analyst | Firm | Price target | Rating | Upside | Action | Date | Move vs SPY | |
|---|---|---|---|---|---|---|---|---|
| AI xAi Medical - Diagnostics and ResearchxAI Grok-3 | TipRanks - xAI | $74.00 → $68.00−8.1% | Hold | +6.9% | Reiterated | 17.10.26on TipRanks 06:07 | — | |
| AI DeepSeek Medical - Diagnostics and ResearchDeepSeek V3.2-Speciale | TipRanks - DeepSeek | $70.00 → $65.00−7.1% | Hold | +2.2% | Reiterated | 17.10.26on TipRanks 05:05 | — | |
| AI OpenAI Medical - Diagnostics and ResearchOpenAI 5.2 | TipRanks - OpenAI | $73.00 → $67.00−8.2% | Hold | +5.3% | Reiterated | 17.10.26on TipRanks 05:05 | — | |
| AI Anthropic Medical - Diagnostics and ResearchAnthropic Opus-4.5 | TipRanks - Anthropic | $71.00 → $66.00−7.0% | Hold | +3.8% | Reiterated | 17.10.26on TipRanks 05:05 | — | |
| AI Google Medical - Diagnostics and ResearchGemini 3-pro | TipRanks - Google | $73.00 → $68.00−6.8% | Hold | +6.9% | Reiterated | 17.10.26on TipRanks 05:05 | — | |
| AI PerPlexity Medical - Diagnostics and ResearchPerPlexity SonarPro | TipRanks - PerPlexity | $71.00 → $66.00−7.0% | Hold | +3.8% | Reiterated | 17.10.26on TipRanks 05:05 | — | |
| Subbu Nambi★★★★★★★★★★#281 · hits 72% · avg +34.4% | Guggenheim | $74.00 → $83.00+12.2% | Buy | +30.5% | Reiterated | 01.10.26on TipRanks 08:35 | −2.0%next day +2.3% · 5 days −5.9% | ↗ |
| William Bonello★★★★★★★★★★#152 · hits 66% · avg +35.0% | Craig-Hallum | $103 | Buy | +61.9% | Reiterated | 22.09.26on TipRanks 11:55 | −7.2%next day −5.4% · 5 days −15.3% | ↗ |
| Keith Hinton★★★★★★★★★★#7123 · hits 80% · avg +7.0% | Freedom Capital Markets | $93.00 → $102+9.7% | Buy | +60.4% | Reiterated | 11.08.26on TipRanks Sep 27 05:10 | +5.3%next day +0.5% · 5 days −6.2% | ↗ |
| Mark Massaro★★★★★★★★★★#2635 · hits 40% · avg +5.7% | BTIG | $90.00 | Buy | +41.5% | Reiterated | 04.08.26on TipRanks 07:56 | +2.7%next day −1.2% · 5 days +15.4% | ↗ |
| Kyle Mikson CFA★★★★★★★★★★#2814 · hits 38% · avg +5.9% | Canaccord Genuity | $75.00 → $90.00+20.0% | Buy | +41.5% | Reiterated | 04.08.26on TipRanks 07:50 | +2.7%next day −1.2% · 5 days +15.4% | ↗ |
| David Westenberg★★★★★★★★★★#602 · hits 56% · avg +17.3% | Piper Sandler | $63.00 | Buy | −1.0% | Reiterated | 04.08.26on TipRanks 07:45 | +2.7%next day −1.2% · 5 days +15.4% | ↗ |
| Daniel Brennan★★★★★★★★★★#271 · hits 58% · avg +21.8% | TD Cowen | $55.00 → $85.00+54.5% | Buy | +33.6% | Reiterated | 15.07.26on TipRanks 08:55 | +5.5%next day −6.2% · 5 days −4.4% | ↗ |
| Tycho Peterson★★★★★★★★★★#1097 · hits 57% · avg +9.8% | Jefferies | $100 | Buy | +57.2% | Reiterated | 27.05.26on TipRanks 11:05 | −2.5%next day +3.5% · 5 days +9.5% | ↗ |
| No ratings for this filter. | ||||||||
The latest rating of each analyst in the last 12 months, as TipRanks lists them. Every rating kept, earlier ones included
Best analysts covering GeneDx Holdings
TipRanks picks them by their record on this stock; the figures under the name are their record across all their ratings.
Most accurate
Most profitable
How the average price target moved
The average target of all analysts (their ratings of the 3 months before) on each day, the top analysts’ dashed, against the price; the site keeps this record since 1 October 2026. On 01.10.26: target $88.00 at a price of $72.30 (+21.7%); now: $88.50 at $63.61 (+39.1%).
PriceAverage targetTop analysts’ target
Recommendation trend · top analysts
Strong BuyBuyHoldSell
| Rating | 05.26 | 06.26 | 07.26 | 08.26 | 09.26 | 10.26 |
|---|---|---|---|---|---|---|
| Strong Buy | 13 | 9 | 8 | 0 | 0 | 0 |
| Buy | 2 | 5 | 7 | 11 | 9 | 7 |
| Hold | 0 | 0 | 0 | 0 | 1 | 1 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
Earnings and sales forecast
Next report: 03.11.26 (Q3 2026, date not confirmed)
Earnings per share
Next quarter’s EPS estimate — $0.07 (from $0.07 to $0.08). Last quarter: $0.01.
Sales
Next quarter’s sales estimate — $123M (from $122M to $124M). Last quarter: $114M.
Best top-analyst consensus in the sector · Healthcare
About GeneDx Holdings
- CEO: Katherine A. Stueland
- Employees: 1,300
- North Tower, Stamford, CT, 06902, US
- www.genedx.com
GeneDx Holdings Corp., a genomics company, provides genetic testing services. The company primarily offers pediatric and rare disease diagnostics with a focus on whole exome and genome sequencing, as well as data and information services. It also develops an AI-based platform for next generation sequencing analysis, interpretation, and clinical reporting for rare disease, hereditary risk, and cancer testing. GeneDx Holdings Corp. was founded in 2000 and is headquartered in Stamford, Connecticut.
Data from the stock’s TipRanks forecast page, read 13 min ago. It is read again as soon as a new rating appears and at least every 8 hours. TipRanks ↗